Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Bispecific CAR T-cell therapy as treatment for hard to treat multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.12.19
Views: 381

Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China

Dr Yu Hu speaks to ecancer at the ASH 2019 meeting in Orlando about a study looking at the use of bispecific CAR T-cell therapy as treatment for hard to treat multiple myeloma.

Dr Hu explains that usually CAR T-cell therapies target one antigen but this new therapy can target two: Bcma and CD38.

He reports that the study demonstrated improved efficacy with a high overall response rate and also was effective in eliminating for extramedullary tumours.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Watch the press conference here

Read more about the study here

Related videos

follow us

Biosimilar Medicines Core Principles and Communication

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation